Institution Directory

Clinical trials at Ohio State University Wexner Medical Center

Sites in Columbus, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1585

Shown on this page

Current sort

Live official records

Conditions: Multiple Sclerosis
Interventions: Frexalimab, MRI contrast-enhancing preparations; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 34
States / cities: Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 29 more

Conditions: Diabetic Retinopathy
Interventions: RO7663498; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Glendale, California • Oak Forest, Illinois • Columbus, Ohio + 1 more

Conditions: Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant, Recurrent Astrocytoma, IDH-Mutant, Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
Interventions: Biospecimen Collection, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Triapine; Procedure · Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 43
States / cities: Duarte, California • Irvine, California • La Jolla, California + 34 more

Conditions: Endometrial Cancer
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel, Sacituzumab Tirumotecan, Cisplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 53
States / cities: Mobile, Alabama • Anchorage, Alaska • Irvine, California + 47 more

Conditions: Parkinson's Disease
Interventions: Deep Brain Stimulation (DBS); Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2038
U.S. locations: 29
States / cities: Aliso Viejo, California • Los Angeles, California • Aurora, Colorado + 25 more

Conditions: Chondral Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Defect, Articular Cartilage Disorder of Knee
Interventions: MACI, microfracture; Biological · Procedure
Lead sponsor: Vericel Corporation; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 14
States / cities: Palo Alto, California • Sacramento, California • New Orleans, Louisiana + 9 more

Conditions: Extrapulmonary Neuroendocrine Cancer (epNEC)
Interventions: Obrixtamig, Carboplatin, Etoposide, Ventana DLL3 RxDx assay; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 21
States / cities: Scottsdale, Arizona • Duarte, California • San Francisco, California + 17 more

Conditions: Non-small Cell Lung Cancer
Interventions: Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib, Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib; Drug · Procedure
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 38
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 28 more

Conditions: Pancreatic Cyst
Interventions: Not listed
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 10
States / cities: Scottsdale, Arizona • Stanford, California • New Haven, Connecticut + 7 more

Conditions: Acute Ischemic Stroke
Interventions: BB-031, Placebo; Drug
Lead sponsor: Basking Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 15
States / cities: Scottsdale, Arizona • Burlingame, California • Long Beach, California + 11 more

Conditions: Cervical Cancer
Interventions: Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab, Paclitaxel, Cisplatin, Carboplatin, Rescue Medications; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,023 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 30
States / cities: Birmingham, Alabama • Anchorage, Alaska • Irvine, California + 25 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Carboplatin, Computed Tomography, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Sacituzumab Govitecan, Tremelimumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 30
States / cities: Orange, California • Sacramento, California • Aurora, Colorado + 22 more

About this Ohio State University Wexner Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Ohio State University Wexner Medical Center in Columbus, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Ohio State University Wexner Medical Center

Filter and sort this campus

Live official records

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions

Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

About this Ohio State University Wexner Medical Center institution page